MET: a new promising biomarker in non-small-cell lung carcinoma.
about
Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancerEvolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance.Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer.Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients.Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function.Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance.
P2860
MET: a new promising biomarker in non-small-cell lung carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
MET: a new promising biomarker in non-small-cell lung carcinoma.
@en
type
label
MET: a new promising biomarker in non-small-cell lung carcinoma.
@en
prefLabel
MET: a new promising biomarker in non-small-cell lung carcinoma.
@en
P2093
P2860
P356
P1433
P1476
MET: a new promising biomarker in non-small-cell lung carcinoma.
@en
P2093
Cristina Pérez-Ramírez
María José Faus-Dáder
Miguel Ángel Calleja-Hernández
P2860
P304
P356
10.2217/PGS.15.11
P577
2015-04-20T00:00:00Z